Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Decreases By 21.6%

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the target of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 62,600 shares, a decline of 21.6% from the May 15th total of 79,800 shares. Based on an average daily volume of 160,500 shares, the short-interest ratio is currently 0.4 days. Currently, 0.7% of the shares of the company are short sold.

Monopar Therapeutics Stock Performance

MNPR stock traded up $0.03 during trading on Friday, hitting $0.94. The company had a trading volume of 117,140 shares, compared to its average volume of 178,243. The firm has a 50-day moving average price of $0.70 and a 200-day moving average price of $0.59. Monopar Therapeutics has a 1-year low of $0.27 and a 1-year high of $1.73.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Thursday, May 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. As a group, equities research analysts forecast that Monopar Therapeutics will post -0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

MNPR has been the subject of several research analyst reports. Jonestrading raised Monopar Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Thursday, April 11th. HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Monopar Therapeutics in a research note on Friday, May 10th.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.